#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16500	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2087	786.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1430	1430	C	966	C,G	899,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29646	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3787	781.3	0	.	n	.	0	T695C	SNP	695	695	T	1174	1174	C	959	C,T	889,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29646	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3787	781.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1816	1816	A	962	A	895	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29646	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3787	781.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2450	2450	C	951	C	868	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29646	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3787	781.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2524	2524	A	922	A	869	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29646	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3787	781.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3076	3076	C	925	C	866	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	784	16	blaTEM	861	532	100.0	blaTEM.l6.c4.ctg.1	560	2.2	0	.	p	.	0	I244M	NONSYN	730	732	ATT	394	396	ATG	1;1;1	A;T;G,T	1;1;0,1	.	Betalactam resistance
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2012	folP	852	852	100.0	folP.l15.c4.ctg.1	1410	141.8	1	SNP	p	R228S	1	.	.	682	684	AGC	959	961	AGC	203;201;203	A;G;C	190;187;188	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5412	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3343	161.6	1	SNP	p	S91F	0	.	.	271	273	TCC	556	558	TCC	215;211;213	T;C;C	200;195;199	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5412	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3343	161.6	1	SNP	p	D95N	0	.	.	283	285	GAC	568	570	GAC	207;205;208	G;A;C	193;190;195	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5412	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3343	161.6	1	SNP	p	D95G	0	.	.	283	285	GAC	568	570	GAC	207;205;208	G;A;C	193;190;195	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1732	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1179	145.7	0	.	p	.	0	A39T	NONSYN	115	117	GCC	386	388	ACC	213;214;214	A,G,C;C;C	183,1,1;197;195	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1732	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1179	145.7	0	.	p	.	0	R44H	NONSYN	130	132	CGC	401	403	CAC	215;216;218	C;A,G;C	199;197,2;204	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1732	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1179	145.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	584	586	CAC	234;234;234	C;A;C	219;211;216	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1732	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1179	145.7	1	SNP	p	G45D	0	.	.	133	135	GGC	404	406	GGC	218;217;216	G;G,A;C	204;200,1;202	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	938	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	1057	88.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5412	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2935	183.7	1	SNP	p	D86N	0	.	.	256	258	GAC	572	574	GAC	214;214;212	G;A;C	201;197;200	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5412	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2935	183.7	1	SNP	p	S87I	0	.	.	259	261	AGT	575	577	AGT	212;213;212	A;G;T	198;200;196	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5412	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2935	183.7	1	SNP	p	S87R	0	.	.	259	261	AGT	575	577	AGT	212;213;212	A;G;T	198;200;196	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5412	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2935	183.7	1	SNP	p	S87W	0	.	.	259	261	AGT	575	577	AGT	212;213;212	A;G;T	198;200;196	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5412	parC	2304	2304	100.0	parC.l6.c30.ctg.1	2935	183.7	1	SNP	p	S88P	0	.	.	262	264	TCC	578	580	TCC	208;207;206	T;C,T;C	194;195,1;196	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4586	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2508	182.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1468	1470	GGC	252;249;248	G,T;G;C	234,1;230;227	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1256	1258	GCA	237;237;238	G;C;A	215;217;220	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1259	1261	ATC	235;239;242	A;T,C;C	217;221,1;225	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1271	1273	GTG	237;237;235	G;T;G	219;217;216	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1271	1273	GTG	237;237;235	G;T;G	219;217;216	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1775	1777	ACC	215;216;213	A;C;C	195;197;199	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1829	1831	GCG	180;182;184	G;C;G	159;149;155	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1829	1831	GCG	180;182;184	G;C;G	159;149;155	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1952	1954	GGC	186;183;180	G;G;C	166;163;166	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1961	1963	GGC	183;180;182	G;G;C	165;167;171	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4316	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2494	172.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1979	1981	CCG	159;159;159	C,G;C;G	116,7;117;116	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5892	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3045	192.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1516	1518	CTG	198;199;197	C;T,C;G	175;179,1;176	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2380	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1817	130.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	581	581	C	187	C	168	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	333	335	GGA	257;253;256	G;G,A;A	234;230,1;232	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	G50D	NONSYN	148	150	GGC	339	341	GAC	253;254;257	G;A;C	230;230;234	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	K130E	NONSYN	388	390	AAA	579	581	GAA	222;221;220	G;A;A	208;209;207	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	F135L	NONSYN	403	405	TTT	594	596	CTT	213;216;216	C;T;T	197;198;200	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	R143G	NONSYN	427	429	AGA	618	620	GGA	229;229;228	G;G;A	207;206;204	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	D171G	NONSYN	511	513	GAT	702	704	GGT	238;239;239	G;G;T	220;222;211	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	G189S	NONSYN	565	567	GGC	756	758	AGC	221;224;225	A;G;C	208;209;207	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	0	.	p	.	0	K208fs	FSHIFT	622	622	A	813	813	A	204	A	193	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	1	SNP	p	G120K	0	.	.	358	360	GGT	549	551	GGT	221;221;220	G;G;T	207;206;206	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	1	SNP	p	A121N	0	.	.	361	363	GCC	552	554	GCC	223;222;227	G;C;C	208;208;213	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2948	porB1b	1035	1035	96.43	porB1b.l15.c17.ctg.1	1360	214.2	1	SNP	p	A121D	0	.	.	361	363	GCC	552	554	GCC	223;222;227	G;C;C	208;208;213	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12154	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	4921	246.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2076	2078	AAT	293;288;290	A,C;A;T	270,1;267;264	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1232	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	909	133.8	1	SNP	p	V57M	1	.	.	169	171	ATG	488	490	ATG	258;261;259	A;T;G	235;239;235	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
